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We hypothesize that PKC ε- treated I/R hearts compared to untreated I/R 
hearts will exhibit improved post-reperfused cardiac function and regional  
coronary flow.   
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Initial LVESP 
(mmHg) 105.8 ± 5.6 95.3 ± 3.8 97.6 ± 1.9 98.7  ± 3.6 98.0 ± 3.6 103.7 ± 4.2 101.8 ± 3.8 96.0 ± 2.8 108.9 ± 5.3 
Final LVESP 
(mmHg) 104.5 ± 6.6 83.4 ±  6.8
# 91.9 ± 7.3 103.3 ± 5.7 83.2 ± 9.9 97.9 ± 5.8 121.2 ± 5.4** 114.2 ± 12.7 103.7 ± 10.7 
Initial LVEDP 
(mmHg) 11.6 ± 2.6 8.5 ± 1.2 9.4 ± 0.3 11.3 ± 0.7 7.3 ± 0.7 9.5 ± 0.5 10.0 ± 0.8 7.2 ± 0.6 11.5 ± 2.5 
Final LVEDP 
(mmHg) 12.8 ± 3.2 14.4 ± 6.0 9.5 ± 0.2 61.6 ± 5.1 56.1 ± 9.2 61.1 ± 6.7 45.3 ± 3.8* 53.3 ± 9.1 37.4 ± 5.7* 
Initial 
+dP/dtmax 
(mmHg/sec) 
2350.4 ± 61.0 2334.1 ± 88.5 2370.5 ± 71.6 2323.5 ± 68.5 2394.8 ± 135.9 2522.9 ± 82.3 2345.4 ± 61.7 2413.7 ± 76.7 2514.8 ± 109.8 
Final 
+dP/dtmax 
(mmHg/sec) 
2294.1 ± 117.6 1786.7 ± 201.4 2184.4 ± 151.3 877.6 ± 96.7 513.5 ±  91.9 # 747.9 ± 172.9 1666.6 ± 120.7 ** 1379.1 ± 158.4** 1482 ± 193.2* 
Initial 
 -dP/dtmin 
(mmHg/sec) 
- 1619.5 ± 73.5 -1619. 5 ± 87.1 -1577.2 ± 53.9 -1540.2 ± 68.4 -1579.7 ± 125.9 -1746.4 ± 109.3 -1547.6 ± 52.0 -1587.8 ± 68.0 -1680.1 ± 182.7 
Final  
- dP/dtmin 
(mmHg/sec) 
-1526.3 ± 86.6 -1153.4 ± 129.3# -1378.6 ± 122.2 -750.7 ± 52.7 -386.5 ± 80.1 # -573.5 ± 93.2 -1190.4 ± 79.4** -914.8 ± 100#** -858.8 ± 211.2 
Initial 
coronary 
flow 
(mL/min) 
17.8 ± 2.1 18.4  ± 1.5 16.87 ± 0.9 16.6 ± 1.3 16.6 ± 0.9 19.7 ± 1.2 16.8 ± 0.6 17.5 ± 0.8 21.0 ± 3.4 
Final 
coronary 
flow 
(mL/min) 
17.1 ± 2.3 16.6 ± 1.6 17.6 ± 0.9 7.7 ± 0.5 8.2 ± 0.7 10.0 ± 1.1 12.0 ± 1.1** 8.1 ± 0.7# 11.7 ± 4.7 
Initial Heart 
Rate (BPM) 265.6 ± 5.3 302.2  ± 15.0 296.8 ± 12.3 276.1 ± 13.5 274.5 ± 7.1 290.7 ± 6.8 279.8 ± 5.9 297.1 ± 10.2 276.9 ± 4.8 
Final Heart 
Rate (BPM) 266.5 ± 10.6 276. 2 ± 8.9 279.1 ±11.7 239.8 ± 15.6 225.3 ± 21.8 254.8 ± 7.0 268.8 ± 11.2 235.9 ± 10.2 265.4 ± 16.6 
Figure 1. Schematic representation of PKCε regulation of mitochondrial and uncoupled 
eNOS superoxide (O2-)  release in myocardial I/R (left) and mechanism of action of PKCε- 
(right; adapted [3]). I/R insult activates PKC (e.g., PKCε) and causes overproduction of O2- 
mainly from damaged mitochondria. The oxidative stress leads to eNOS uncoupling  which 
produces O2- instead of NO resulting in vascular endothelial dysfunction. Activated PKCε 
enhances eNOS activity and opens mitochondrial ATP-dependent potassium channels 
causing exacerbation of I/R injury during reperfusion. By contrast, PKCε- inhibits PKCε 
translocation to interact with both substrates by binding to the PKCε receptor for activated 
C kinase (RACK) domain (see right panel) to provide cardioprotective effects.  
Following an acute myocardial infarction, reperfusion of blood flow to the 
ischemic myocardium, although necessary, leads to compromised heart 
function resulting in MI/R injury. PKC epsilon positively regulates eNOS 
activity. During I/R, PKC epsilon peptide inhibitor (PKCε-) inhibits uncoupled 
eNOS activity and attenuates mitochondrial damage to reduce superoxide 
and inhibits  the induction of the inflammatory response (Fig. 1) [1, 2]. To 
further evaluate the cardioprotective effects of PKCε- in MI/R injury, we 
assessed regional blood flow by measuring regional microsphere 
fluorescence density after injecting fluorescent microspheres into isolated 
perfused rat hearts subjected to I (30 min)/ R (45 min) with/without PKCε- 
Untreated sham (i.e., no I/R) hearts without microsphere maintained cardiac contractile function throughout the experimental time period.  By contrast, sham 
hearts that received triple microsphere injections showed a significant decrease in left ventricular developed pressure (LVDP) (i.e.,  left ventricular end-systolic 
pressure (LVESP) minus left ventricular end-diastolic pressure [LVEDP]) and this effect is attributed to a significant decrease in  LVESP and  - dpdt min (Fig. 3).   
For LVDP percent recovery of baseline:  
• Untreated I/R hearts recovered to 48 ± 5%                                                                     • PKCε- treated I/R hearts recovered to 83 ± 6%  
 
•  Untreated I/R hearts with triple microsphere injections recovered to 30 ± 6%        • PKCε- treated I/R hearts with triple microsphere injections recovered to 70± 8%  
 
•  Untreated I/R  hearts single microsphere injection recovered to 39 ± 7%                 • PKCε- treated I/R hearts single microsphere injection recovered to 68 ± 12%           
 
 
Isolated Rat Heart Perfusion Preparation: Hearts were isolated from  
male Sprague Dawley rats (275-325g, Charles River, Springfield MA) via 
Langendorff heart preparation as previously described [4]. Experimental 
protocol  represented in Fig. 2.  
Microsphere Injections: Polystyrene Microspheres (FluoSpheres, 
ThermoFisher Scientific), Kit #4, 15 μm diameter, 1.0 X 106 beads/ml, were 
used to evaluate regional coronary flow [5]. Fifteen µL of a stock microsphere 
solution was diluted with 1,485 µL of 37°C Krebs’ buffer to a final volume of 
1.5 mL of microsphere injection solution. One mL microspheres manually 
injected into the heart via retrograde perfusion at a rate of 1mL/minute for a 
total of approximately 10,000 microspheres per injection.    
Tissue Digestion & Microsphere Extraction: 
Microspheres were dissolved in  
2-ethoxyethyl acetate and 100 μL samples were 
plated in 96 well round bottom black 
polypropylene plates [6]. Fluorescence intensity 
was measured with a HORIBA  FluoroMax Series 
spectrofluorometer.  
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Figure  3. Initial           and final          LVDP expressed in mmHg from isolated perfused rat hearts before ischemia (I) (initial) and after 45 min postreperfusion (R) (final). All 
cardiovascular parameter values are expressed as means ± S.E.M. , # p<0.05 compared to group control (i.e. no microspheres) final cardiac function parameters.  *p<0.05, 
**p<0.01 compared to matched I/R groups (with or without microspheres) final cardiac function parameters. There were no differences in initial cardiac function parameters 
among all study groups  
                                       
Figure 4. Comparison of ratio of fluorescence per gram tissue weight between 
PKCε- treated I/R hearts (n=8) and untreated I/R (n=7) hearts in right ventricle,  
septum, and left ventricle  in triple microsphere injected hearts.  
Figure 2. Flow diagram of an experimental protocol     
Statistical Analysis: All data in the figures are presented as means ± S.E.M. 
A student’s t-test was used to assess statistical difference in cardiac 
functions and  microsphere fluorescence between I/R and I/R + PKCε- 
hearts. Probability values of < 0.05 were considered statistically significant. 
 Triple Microsphere Injections  Single Microsphere Injections  
@ 45 min post-reperfusion 
No Microsphere Injections  
Microsphere fluorescence is theorized to be representative of coronary 
regional flow.  Data in figure 4. show a ratio of the microsphere 
fluorescence per gram tissue weight between PKCε- treated I/R hearts and 
untreated I/R hearts in right ventricle, septum, and left ventricle. PKCε-  
treated I/R hearts showed an increase in mean fluorescence by almost two-
fold in the left ventricle at 45 minutes of reperfusion.  Whereas the right 
ventricle and septum show equivalent mean fluorescence compared to the 
left ventricle at 45 min reperfusion. 
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As expected, PKCε- treated I/R hearts showed significant improvement in 
almost all final cardiac function parameters (LVDP, LVESP, etc.) regardless 
of exposure to single or triple microsphere injections. Under all 
conditions, PKCε- treated I/R hearts exhibited improved coronary flow  in 
the left ventricle and this improvement in flow probably underlies  the 
improvement in cardiac performance.  
 
Determination of regional coronary flow using  microspheres allows for a 
direct correlation between left ventricular coronary flow and left 
ventricular cardiac function. As evidenced by the data  in Fig. 3, coronary 
flow between PKCε- treated I/R hearts (n=8) and I/R hearts (n=7) were 
equivalent, yet regional flow in the left ventricle measured by 
microspheres  was significantly increased in PKCε- treated I/R hearts, see 
Fig. 4. Our findings suggest that the ex vivo rat heart is sensitive to 
reductions in oxygen concentration in Krebs’ buffer. Such that detectable 
levels of microspheres induce measurable depression of cardiac function. 
Future experiments will determine the fluorescence  in the single injection 
45 min reperfusion experiments.  
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